AI Stock Analysis - Eli Lilly and Company (LLY)
Analysis generated February 16, 2026.
Eli Lilly and Company is a renowned global healthcare leader primarily engaged in the development, manufacture, and marketing of pharmaceutical products. Established in 1876, it has a long history of innovation with a robust pipeline of new drugs and therapies that aim to improve patient outcomes across various therapeutic areas such as diabetes, oncology, immunology, neuroscience, and more. The company's portfolio includes several blockbuster drugs, and it continues to invest heavily in research and development to sustain its market-leading position.
Stock Alerts - Eli Lilly and Company (LLY)
 |
Eli Lilly and Company | March 13 David Taylor (member of U.S. congress) is buying shares |
|
Eli Lilly and Company | March 4 Over the past few months, there has been a noticeable upward trend in Instagram Followers. |
|
Eli Lilly and Company | February 23 David Taylor (member of U.S. congress) is selling shares |
|
Eli Lilly and Company | February 5 Price is down by -6.5% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Eli Lilly and Company
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 909 | Sign up | Sign up | Sign up |
| Sentiment | 83 | Sign up | Sign up | Sign up |
| Webpage traffic | 6,936,000 | Sign up | Sign up | Sign up |
| Employee Rating | 80 | Sign up | Sign up | Sign up |
| Google Trends | 96 | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 8,588 | Sign up | Sign up | Sign up |
| Facebook Followers | 272,089 | Sign up | Sign up | Sign up |
| Instagram Followers | 69,545 | Sign up | Sign up | Sign up |
| Reddit Mentions | 4 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 171 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 31,849 | Sign up | Sign up | Sign up |
| X Followers | 142,899 | Sign up | Sign up | Sign up |
| X Mentions | 137 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 83 | Sign up | Sign up | Sign up |
| Linkedin Employees | 54,997 | Sign up | Sign up | Sign up |
About Eli Lilly and Company
Eli Lilly and Co is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. It discovers, develops, manufactures, and sells human pharmaceutical products and animal health products.
| Price | $985.08 |
| Target Price | Sign up |
| Volume | 2,802,169 |
| Market Cap | $882B |
| Year Range | $622.37 - $1108.1 |
| Dividend Yield | 0.61% |
| PE Ratio | 42.92 |
| Analyst Rating | 89% buy |
| Earnings Date | April 30 '26 |
| Industry | Drug Manufacturers |
In the news
Eli Lilly and Company (LLY) Set to Launch Oral Obesity Drug in Q2, Reuters ReportsMarch 10 - Yahoo Entertainment |
|
Eli Lilly and Company (LLY) Announces the Launch of its Employer Connect PlatformMarch 10 - Yahoo Entertainment |
|
Eli Lilly (LLY) Releases Positive Results From Phase 3 VIVID-2 Open-Label Extension StudyFebruary 25 - Yahoo Entertainment |
|
 |
Eli Lilly (LLY) Seen Resilient as BofA Downplays Novo Nordisk GLP-1 Price ImpactFebruary 25 - Yahoo Entertainment |
 |
How The Eli Lilly (LLY) Narrative Is Shifting Around Obesity Leadership And Valuation RisksFebruary 23 - Yahoo |
|
Eli Lilly (LLY) Stock Is Up, What You Need To KnowFebruary 23 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '25 | 19.3B | 2.88B | 16.4B | 6.64B | 8.39B | 7.540 |
| Q3 '25 | 17.6B | 3.01B | 14.6B | 5.58B | 7.88B | 7.020 |
| Q2 '25 | 15.6B | 2.45B | 13.1B | 5.66B | 7.5B | 6.310 |
| Q1 '25 | 12.7B | 2.22B | 10.5B | 2.76B | 4.16B | 3.340 |
| Q4 '24 | 13.5B | 2.4B | 11.1B | 4.41B | 5.75B | 5.320 |
Insider Transactions View All
| LILLY ENDOWMENT INC filed to sell 92,170,934 shares at $1094.7. January 8 '26 |
| LILLY ENDOWMENT INC filed to sell 92,170,459 shares at $1095.7. January 8 '26 |
| LILLY ENDOWMENT INC filed to sell 92,188,231 shares at $1085.1. January 8 '26 |
| LILLY ENDOWMENT INC filed to sell 92,178,547 shares at $1089. January 8 '26 |
| LILLY ENDOWMENT INC filed to sell 92,179,477 shares at $1087.8. January 8 '26 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$241.52 0.2% | 56 |
 |
PfizerPFE |
$26.58 1% | 28 |
 |
AstrazenecaAZN |
$189.9 1.4% | 50 |
 |
AbbVieABBV |
$219.68 2.5% | 61 |
 |
TherapeuticsMDTXMD |
$2.17 4.8% | 39 |
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| David Taylor |
Mar 9, 26 | Buy | $1K - $15K |
| David Taylor |
Feb 23, 26 | Sell | $1K - $15K |
| David Taylor |
Feb 3, 26 | Sell | $1K - $15K |
Read more about Eli Lilly and Company (LLY) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Eli Lilly and Company
The Market Cap of Eli Lilly and Company is $882B.
As of today, Eli Lilly and Company's PE (Price to Earnings) ratio is 42.92.
Eli Lilly and Company will report its next earnings on April 30 '26.
Currently, the price of one share of Eli Lilly and Company stock is $985.08.
The LLY stock price chart above provides a comprehensive visual representation of Eli Lilly and Company's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Eli Lilly and Company shares. Our platform offers an up-to-date LLY stock price chart, along with technical data analysis and alternative data insights.
Yes, Eli Lilly and Company (LLY) offers dividends to its shareholders, with a dividend yield of 0.61%. This dividend yield represents Eli Lilly and Company's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Eli Lilly and Company in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
Some of the similar stocks of Eli Lilly and Company are Johnson & Johnson, Pfizer, Astrazeneca, AbbVie, and TherapeuticsMD.
